Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
Incorporating SGLT-2i into the UHC would significantly impact the healthcare budget. Policymakers should consider this valuable evidence.
Authors
- Piyameth Dilokthornsakul (ORCID: https://orcid.org/0000-0002-6981-1771)
- Mantiwee Nimworapan (ORCID: https://orcid.org/0000-0002-7691-0348)
- Tuangrat Phodha (ORCID: https://orcid.org/0000-0001-7793-0327)
- Poukwan Arunmanakul (ORCID: https://orcid.org/0000-0002-4725-3326)
- Arintaya Phrommintikul (ORCID: https://orcid.org/0000-0003-3986-1951)
- Noppakun Thammatacharee (ORCID: https://orcid.org/0000-0002-7475-9293)
- Sakkarin Pinta-Ay
Institutions
- Thammasat University (TH)
- Maharaj Nakorn Chiang Mai Hospital (TH)
- Health Systems Research Institute (TH)
- Chiang Mai University (TH)
- Rangsit University (TH)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/ceor.s504819
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Health Systems Research Institute